NGF inhibitor Tanuzemab (TNZ) phase III study in patients with low back pain - H2H against placebo and tramadol. At 16 wks, ≥50% improvement in LBPI was 37%, 43% TNZ 5mg and 46% TNZ 10mg (Odds ratio [95% CI] vs placebo = 1.45 [1.09, 1.91; P=0.0101]). https://t.co/3DvUHtxcqk